| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$230.7M | ROE | −149.49% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Kodiak Sciences is a clinical-stage biopharmaceutical company researching, developing, and commercializing therapeutics for retinal diseases. Its lead candidate, tarcocimab tedromer (KSI-301), is an anti-VEGF antibody biopolymer studied in Phase 3 for retinal vascular diseases including diabetic retinopathy, wet AMD, retinal vein occlusion, and diabetic macular edema. Preclinical candidates include KSI-501 and KSI-101, bispecific agents targeting IL-6 and VEGF for retinal vascular diseases.
| Market Cap | $2.52B | Trading Days | 1957 |
| 52W High | 47.84 |
| 52W Low | 6.21 |
| % Off High | −15.78% |
| YTD | 44.10% | 1Y | 388.96% |
| 3Y | 1303.83% | 5Y | −56.15% |
| Since incept. (ann.) | 19.28% |
| Ann. Volatility (1Y) | 132.85% | Ann. Volatility (3Y) | 114.87% |
| Sharpe (1Y) | 1.78 | Sharpe (3Y) | 1.30 |
| Max Drawdown (1Y) | −36.24% | Max Drawdown (3Y) | −81.10% |
| Beta (3Y, vs SPY) | 2.39 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| TARS | Tarsus Pharmaceuticals, Inc. | $2.54B | — |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $2.48B | 8.0 |
| VCEL | Vericel Corp | $2.39B | 146.0 |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.35B | — |
| BEAM | Beam Therapeutics Inc. | $2.70B | — |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $2.10B | — |
| ADMA | ADMA BIOLOGICS, INC. | $2.04B | 14.6 |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.86B | — |
| RLAY | Relay Therapeutics, Inc. | $3.50B | — |
| ADPT | Adaptive Biotechnologies Corp | $3.60B | — |
| SCNI | Scinai Immunotherapeutics Ltd. | $3.66B |
| — |
| IMCR | Immunocore Holdings plc | $1.70B | — |
